A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis

Phase 2 Completed 168 enrolled Shanghai Genomics, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

To explore the effective dose and safety of the effect of hydronidone and entecavir on hepatic fibrosis in chronic viral hepatitis B.

Evaluation	Drug	Modality	Dose	Route
Subject	Hydronidone	Small molecule	180 mg	Oral
Subject	Hydronidone	Small molecule	270 mg	Oral
Subject	Hydronidone	Small molecule	360 mg	Oral
Background	Entecavir	Small molecule	0.5 mg	Oral